Genvoya’s per-patient cost also had increased, rising more than $8,000 in four years to $32,196 in 2022, according to the board’s report on that drug.

A Colorado board has named five drugs it will review for affordability and potential cost caps. But patients with cystic fibrosis worry they will lose access to a life-changing therapy.

Colorado’s new Prescription Drug Affordability Board could set price caps on the costly medications Enbrel, Genvoya, Cosentyx, Stelara and Trikafta.

HIV medications help people with HIV lead longer, healthier lives. They're an essential part of taking care of yourself. But AIDS and HIV drug side effects are also common. These side effects ...

Colorado’s Prescription Drug Affordability Board could end up limiting access to the life-saving cystic fibrosis medication Trikafta.

Its leading drugs include HIV drugs Biktarvy and Genvoya, and antiviral medication Veklury. Hellweg says Gilead is a market leader in both HIV and oncology.

The analysts “wouldn’t be surprised” if Biktarvy, Gilead’s blockbuster HIV treatment, was included among the drugs selected for price negotiations in 2028 as part of the Inflation ...

Colorado’s new Prescription Drug Affordability Boardhas identified five costly medications that could receive state-mandated price ceilings — but it’s not clear how that will affe… ...

Imodium is a brand-name drug used to treat diarrhea. Discover drug interactions in-depth, when to avoid Imodium, and more.

Two years ago, a Prescription Drug Affordability Board was established in Colorado. This year, its reviewing five drugs to consider capping prices.

After a Colorado board that reviews prescription drug prices deemed the medicine Enbrel unaffordable, the arthritis drug’s maker filed a lawsuit.

Colorado could be the first state to bring action against a drug maker via a state prescription drug affordability board, over Amgen's drug Enbrel.